ImmunoPrecise Antibodies Ltd. Advances Universal Dengue Vaccine Initiative to Preclinical Manufacturing Stage
I'm PortAI, I can summarize articles.
ImmunoPrecise Antibodies Ltd. has advanced its universal dengue vaccine initiative to the preclinical manufacturing stage, focusing on in vivo testing and virus neutralization analysis. This follows the validation of a conserved dengue epitope using their LENSai™ platform and HYFT® technology. The vaccine candidate will be tested using proprietary immunization protocols at their Canadian facility, with results pending. This marks a significant step in their translational development efforts across infectious diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments